MOTION PROCESSING IN SCHIZOPHRENIA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 平稳追踪眼球运动异常（SPEM）在大约40%的精神分裂症患者和一部分非患病的一级生物学亲属中观察到。后者表明SPEM缺陷标志着精神分裂症的易感性。本申请的目标是鉴定精神分裂症中SPEM表型的特定神经认知机制。一个特定的生理缺陷可能更接近基因的影响，因此更准确地确定一个同质的亚组的个人与精神分裂症的易感性。本工作对精细化表型在精神分裂症分子遗传学和病理生理学研究中的应用具有重要意义。我们将测试精神分裂症患者，他们的一级亲属显示出精神分裂症倾向的其他证据（即，精神分裂症谱系人格（SSP症状，SSP）和无精神病家族史的社区受试者。这项研究将分两个阶段进行。在初始阶段，我们将对每个诊断类别的5-10名受试者进行测试，以确保新设计的任务和设备正常工作。一旦初步测试完成，我们将招募30名精神分裂症受试者，30名SSP一级亲属，60名健康的、无精神分裂症家族史的社区受试者（其中30名在无精神病家族史的情况下表现出SSP症状）。将在这些受试者中进行一系列认知、运动感知和眼动任务。一些测试将在约翰霍普金斯大学的图拉诺博士的实验室进行。所有测试均采用标准非侵入性方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Smooth pursuit eye movement abnormality (SPEM) is observed in about 40% of schizophrenic patients and a proportion of their non-ill, first-degree biological relatives. The latter suggests that the SPEM deficit marks schizophrenia liability. The goal of the current application is to identify the specific neurocognitive mechanisms underlying the SPEM phenotype in schizophrenia. A specific physiological deficit is likely to be more proximal to the effects of genes, and therefore more accurate in identifying a homogenous subgroup of individuals with schizophrenia liability. This work has significance for use of the refined phenotype in molecular genetic and pathophysiologic studies of schizophrenia. We will test patients with schizophrenia, their 1st degree relatives who show other evidence of schizophrenia liability (i.e., schizophrenia spectrum personality (SSP) symptoms, SSP), and community subjects with no family history of psychotic illness. The study will be carried in out in two phases. In the initial phase we will test groups of 5-10 subjects from each diagnostic category in order to insure that newly designed tasks and equipment are working properly. Once the pilot testing is completed, we will recruit 30 subjects with schizophrenia, 30 1st degree relatives with SSP, 60 healthy, community subjects with no family history of schizophrenia (30 of whom exhibit SSP symptoms in the absence of a family history of psychotic illness). A battery of cognitive, motion perception and eye movement tasks will be administered in these subjects. Some of the testing will be carried out in Dr. Turano's laboratory at Johns Hopkins. Standard non-invasive methods are used for all testing.